In KEYNOTE-590 trial, pembrolizumab plus chemotherapy improved OS (p < 0.001) and PFS (p < 0.001) in ESCC participants with PD-L1 CPS ≥ 10 versus chemotherapy alone (11). This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.